‘Yuhan expects Leclaza’s FDA approval this year'
By Kim, Jin-Gu | translator Kim, Jung-Ju
24.02.05 06:18:37
가나다라
0
Wook-Je Cho, President, CEO & Executive Director of Yuhan Corp
“Expect FDA will approve the Rybrevant combination therapy within the year...Will also accelerate trials for second-line therapies"
“Will start clinical trials of its 28 candidates, including those for MASH and obesity, in earnest…on a smooth journey to discovering the company’s ‘next Leclaza’”
Wook-Je Cho (59), President, CEO & Executive Director of Yuhan Corp, has set global commercialization of its new anti-cancer drug Leclaza (lazertinib) as the company’s top priority this year.
Last year, the company focused on the challenge of securing first-line reimbursement coverage for Leclaza in Korea. This year, he plans to move on to the global stage and focus on securing the U.S. Food and Drug Administration (FDA) approval for its Leclaza+Rybrevant combination therapy.
In addition, he emphasized that the company will focus on global clinical trials of 28 drug candidates, including a treatment for metabolic dysfunction-associated steatohepatitis (MASH) and a treatment for obesity, to
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)